



B Cell Lymphoma

Guest Editor:

Dr. Alexey Ushmorov
Institute of Physiological
Chemistry, University of Ulm,
89081 Ulm, Germany

Deadline for manuscript
submissions:
closed (31 January 2021)

Message from the Guest Editor

The B-cell lymphomas are the clonal malignancies derived from mature B cells at different stages of differentiation. Although some of the B-cell lymphoma subtypes are sensitive to conventional chemotherapy and are among the most curable tumors, most of them represent a therapeutic challenge. Importantly, B-cell lymphoma survivors still suffer from acute and delayed treatment complications of aggressive chemotherapy. The introduction of the therapeutic antibodies targeting B-cell markers, followed by the appearance of immune checkpoint inhibitors, and finally CAR-T cell immunotherapy, have further improved treatment results. Unfortunately, these new modalities are not able to cure all patients, and are not free of serious side effects.

This Special Issue is dedicated to broad molecular aspects of B-cell lymphoma pathogenesis and treatment with a focus on the distinctive features of the oncogenic programs of B cell lymphoma subtypes including regulation of transcription, translation, cellular metabolism. We believe that discovering new lineage-specific vulnerabilities and synthetic lethalties will help improve the therapy of B-cell lymphoma.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)